Home | Welcome to Contract Pharma   
Last Updated Friday, September 19 2014
Print

Financial Report: Alkermes



Published May 23, 2013
Alkermes

4Q Revenues: $163.4 million (+25%)

4Q Earnings: $3.0 million (loss of $63.4 million 4Q12)

FY Revenues: $575.5 million (+48%)

FY Earnings: $25.0 million (loss of $113.7 million FY12)

Comments: Revenues from the company’s five key commercial products for the quarter grew 26% to $89.5 million. Results reflect the completion of the merger of Alkermes with Elan Drug Technologies (EDT) in Sept. 2011. For the year, revenues included $50.0 million of intellectual property license revenue unrelated to key development programs.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On